Scientists have mapped previously unknown RNA-protein interactions across the SARS-CoV-2 genome, identifying stable internal targets that could yield antiviral drugs less vulnerable to rapid viral mutation. Published in Nature Communications and detailed by Technology Networks, the research provides an early proof of concept for disrupting essential viral machinery rather than targeting the rapidly evolving spike protein.
Mapping Viral Machinery at UC Riverside and UC San Diego
The study was co-led by Joy Xiang at the University of California, Riverside, and Gene Yeo at the University of California, San Diego. Researchers used enhanced cross-linking and immunoprecipitation, known as eCLIP, to survey the SARS-CoV-2 genome. Instead of limiting their work to pre-predicted regions, the team mapped interactions across the entire genome to uncover unexpected sites involving the RNA-dependent RNA polymerase and the nucleocapsid protein.
Drug Target Review reported that current antivirals like Remdesivir already target the RNA-dependent RNA polymerase enzyme that copies the viral RNA genome. Nirmatrelvir targets proteins involved in processing long protein chains during infection. The new research expands on this approach by identifying specific regulatory touchpoints that remain conserved as the virus mutates.
Did you know?
Researchers used enhanced cross-linking and immunoprecipitation (eCLIP) to map viral protein-RNA interactions across the entire genome rather than examining only pre-selected regions.
Targeting Conserved Regions With Antisense Oligonucleotides
The investigators discovered that the nucleocapsid protein interacts with the 5′ untranslated region at the beginning of the viral genome. This conserved RNA structure helps regulate translation, which is the process the virus uses to manufacture proteins. UC San Diego Today noted that the team identified interactions involving the RNA-dependent RNA polymerase.
To test whether these regions could be disrupted therapeutically, researchers applied antisense oligonucleotides—short, modified nucleic acid sequences designed to bind specific RNA targets. Blocking the interactions significantly reduced viral replication in both African green monkey Vero cells and human lung cells.
Implications for Future Coronavirus Threats
Xiang joined the University of California, Riverside faculty in 2024, funding the subsequent phases of the work using startup funds, a UC Regents Faculty Fellowship, and a University of California, Riverside School of Medicine Dean’s Collaborative Seed Grant. The findings point toward broad-spectrum treatments that could remain effective against multiple coronaviruses and emergent variants.
A 2024 review in Nature Reviews Microbiology highlighted broad-spectrum antivirals as a critical component of pandemic preparedness. However, Xiang noted that the experiments remain at an early stage in cell cultures, and animal studies are required before researchers can determine whether the approach translates into viable human therapeutics.
Frequently Asked Questions About SARS-CoV-2 RNA Interactions
What specific technique did researchers use to map the SARS-CoV-2 genome?
The research team utilized enhanced cross-linking and immunoprecipitation, or eCLIP, to survey the entire viral genome and identify unexpected sites where viral proteins interact with RNA.
How do antisense oligonucleotides disrupt viral replication?
Antisense oligonucleotides are short, modified nucleic acid sequences designed to bind complementary sections of RNA, which blocks those regions from interacting with essential viral proteins and cuts replication rates in cell cultures.
What institutions led the published study?
The study was co-led by the University of California, Riverside, where Joy Xiang serves as an assistant professor, and the University of California, San Diego, under the direction of professor Gene Yeo.
Keep reading